Want to join the conversation?
$ALXN 2Q15 Call: Commercial organization delivered steady growth in both PNH and aHUS, reflecting the strength of core Soliris business. Advanced Strensiq towards commercialization with first approval in Japan and positive CHMP opinion in Europe. In complement franchise, exceeded target enrollment in registration trial of eculizumab.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.